Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 279,273 | 249,717 | 179,413 | 106,355 | 187,024 |
| Cost of Goods | 27,105 | 26,130 | 35,699 | 18,454 | 15,011 |
| Gross Profit | 252,168 | 223,587 | 143,714 | 87,901 | 172,014 |
| Operating Expenses | 249,407 | 210,862 | 204,523 | 198,142 | 170,434 |
| Operating Income | 2,866 | 12,854 | -60,110 | -109,787 | 1,590 |
| Interest Expense | 70,978 | 78,204 | 37,482 | 47,182 | -24,539 |
| Other Income | 32,891 | -1,712 | 57,852 | 58,399 | -64,971 |
| Pre-tax Income | -35,221 | -67,062 | -39,740 | -98,571 | -38,841 |
| Income Tax | 7,690 | 4,228 | 4,368 | 1,118 | 1,150 |
| Net Income Continuous | -42,911 | -71,290 | -44,108 | -99,689 | -39,991 |
| Net Income | $-42,911 | $-71,290 | $-44,108 | $-99,689 | $-39,991 |
| EPS Basic Total Ops | -0.69 | -1.17 | -0.73 | -1.67 | -0.62 |
| EPS Basic Continuous Ops | -0.69 | -1.17 | -0.73 | -1.66 | -0.62 |
| EPS Diluted Total Ops | -0.49 | -1.17 | -0.93 | -1.67 | -0.62 |
| EPS Diluted Continuous Ops | -0.73 | -1.17 | -0.69 | -1.66 | -0.62 |
| EPS Diluted Before Non-Recurring Items | -0.64 | -1.17 | -0.93 | -1.66 | -0.68 |
| EBITDA(a) | $7,841 | $17,851 | $-54,848 | $-104,999 | $6,201 |